UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 446

Sortiert nach

Identification of a bacterial inhibitor against g-type lysozyme

Cellular and molecular life sciences : CMLS, 2011-03, Vol.68 (6), p.1053-1064

2011

Link zum Volltext

Verfügbarkeit prüfen

Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme

Cellular and molecular life sciences : CMLS, 2010-04, Vol.67 (7), p.1177-1188

2010

Link zum Volltext

Verfügbarkeit prüfen

Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

Journal of thrombosis and haemostasis, 2013-01, Vol.11 (1), p.190-192

2013

Link zum Volltext

Verfügbarkeit prüfen

The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

Journal of thrombosis and haemostasis, 2012-12, Vol.10 (12), p.2555-2562

2012

Link zum Volltext

Verfügbarkeit prüfen

Thrombin activatable fibrinolysis inhibitor

Hämostaseologie, 2011, Vol.31 (3), p.165

Declerck, P J

2011

Link zum Volltext

Verfügbarkeit prüfen

The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

The FASEB journal, 2002-02, Vol.16 (2), p.147-154

2002

Link zum Volltext

Verfügbarkeit prüfen

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

British journal of cancer, 2000-05, Vol.82 (10), p.1702-1708

2000

Link zum Volltext

Verfügbarkeit prüfen

Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue : Stimulation by glucocorticoids and inhibition by catecholamines

The journal of clinical endocrinology and metabolism, 1999-11, Vol.84 (11), p.4097-4105

1999

Link zum Volltext

Verfügbarkeit prüfen

Generation of a stable thrombin‐activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation

Journal of thrombosis and haemostasis, 2015-06, Vol.13 (6), p.1084-1089

2015

Link zum Volltext

Verfügbarkeit prüfen

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice

Journal of thrombosis and haemostasis, 2017-12, Vol.15 (12), p.2432-2442

2017

Link zum Volltext

Verfügbarkeit prüfen

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

Journal of thrombosis and haemostasis, 2016-08, Vol.14 (8), p.1629-1638

2016

Link zum Volltext

Verfügbarkeit prüfen

Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors

Journal of thrombosis and haemostasis, 2005-12, Vol.3 (12), p.2745-2753

2005

Link zum Volltext

Verfügbarkeit prüfen

Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a

Journal of thrombosis and haemostasis, 2013-12, Vol.11 (12), p.2137-2147

2013

Link zum Volltext

Verfügbarkeit prüfen

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

Journal of thrombosis and haemostasis, 2010-06, Vol.8 (6), p.1302-1312

2010

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the profibrinolytic properties of a bispecific antibody‐based inhibitor against human and mouse thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1

Journal of thrombosis and haemostasis, 2013-11, Vol.11 (11), p.2069-2071

2013

Link zum Volltext

Verfügbarkeit prüfen

Structure-function relationships in serpins: current concepts and controversies

Thrombosis and haemostasis, 1998-10, Vol.80 (4), p.531

1998

Link zum Volltext

Verfügbarkeit prüfen

Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice

Thrombosis and haemostasis, 1995-11, Vol.74 (5), p.1305

1995

Link zum Volltext

Verfügbarkeit prüfen

Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)

The Journal of biological chemistry, 1988-10, Vol.263 (30), p.15454-15461

1988

Link zum Volltext

Verfügbarkeit prüfen

Identification of a novel, nanobody‐induced, mechanism of TAFI inactivation and its in vivo application

Journal of thrombosis and haemostasis, 2014-02, Vol.12 (2), p.229-236

2014

Link zum Volltext

Verfügbarkeit prüfen

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study

Journal of thrombosis and haemostasis, 2009-06, Vol.7 (6), p.919-927

2009

Link zum Volltext

Verfügbarkeit prüfen

Systemic inhibition and liver‐specific over‐expression of PAI‐1 failed to improve survival in all‐inclusive populations or homogenous cohorts of CLP mice

Journal of thrombosis and haemostasis, 2014-06, Vol.12 (6), p.958-969

2014

Link zum Volltext

Verfügbarkeit prüfen

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

Journal of thrombosis and haemostasis, 2011-11, Vol.9 (11), p.2268-2277

2011

Link zum Volltext

Verfügbarkeit prüfen

Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors

Journal of thrombosis and haemostasis, 2012-04, Vol.10 (4), p.725-727

2012

Link zum Volltext

Verfügbarkeit prüfen

Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis

Journal of thrombosis and haemostasis, 2012-06, Vol.10 (6), p.1091-1099

2012

Link zum Volltext

Verfügbarkeit prüfen

Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1

Thrombosis and haemostasis, 2001-05, Vol.85 (5), p.866

2001

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 446

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(391)
Mit Volltextzugriff
(370)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(324)
Life Sciences & Biomedicine
(298)
Humans
(204)
Biological And Medical Sciences
(134)
Animals
(94)
Female
(87)
Hematology
(87)
Medical Sciences
(81)
Cardiovascular System & Cardiology
(77)
Male
(77)
Peripheral Vascular Disease
(74)
Biochemistry & Molecular Biology
(65)
Fundamental And Applied Biological Sciences. Psychology
(58)
Middle Aged
(54)
Adult
(52)
Fibrinolysis
(49)
Mice
(37)
Plasminogen Activator Inhibitor 1 - Chemistry
(35)
Plasminogen Activator Inhibitor 1 - Metabolism
(35)
Protein Conformation
(33)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Identification of a bacterial inhibitor against g-type lysozyme

Lysozyme inhibitor conferring bacterial tolerance to invertebrate type lysozyme

Plasmin and the thrombin–thrombomodulin complex both contribute to thrombin‐activatable fibrinolysis inhibitor activation in whole blood model thrombi

The hyperfibrinolytic state of mice with combined thrombin‐activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor‐1 gene deficiency is critically dependent on TAFI deficiency

Thrombin activatable fibrinolysis inhibitor

The pro‐ or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent

Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis

Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue : Stimulation by glucocorticoids and inhibition by catecholamines

Generation of a stable thrombin‐activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin‐activatable fibrinolysis inhibitor activation and activated thrombin‐activatable fibrinolysis inhibitor activity

Modulation of TAFI function through different pathways – implications for the development of TAFI inhibitors

Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin‐activatable fibrinolysis inhibitor but not the anti‐inflammatory activity on osteopontin and C5a

Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor

Evaluation of the profibrinolytic properties of a bispecific antibody‐based inhibitor against human and mouse thrombin‐activatable fibrinolysis inhibitor and plasminogen activator inhibitor‐1

Structure-function relationships in serpins: current concepts and controversies

Immunoassay of murine t-PA, u-PA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice

Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)

Identification of a novel, nanobody‐induced, mechanism of TAFI inactivation and its in vivo application

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study

Systemic inhibition and liver‐specific over‐expression of PAI‐1 failed to improve survival in all‐inclusive populations or homogenous cohorts of CLP mice

TAFIa inhibiting nanobodies as profibrinolytic tools and discovery of a new TAFIa conformation

Convalescent plasma levels of TAFI activation peptide predict death and recurrent vascular events in ischemic stroke survivors

Increased zymogen activity of thrombin‐activatable fibrinolysis inhibitor prolongs clot lysis

Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1

Suchergebnisse filtern